Key Highlights

• Q3 2026 revenues were $25.3 million, a decrease of 18.6% compared to $31.1 million in Q3 2025.

• Two new technology transfer projects were secured during the quarter, supporting an NDA and a marketed product.

• Three additional development-phase programmes were signed early in Q4 2026, including one with a top-20 global pharma company.

• Liquidity stood at approximately $38 million, including $23 million in cash and $15 million in revolving Credit availability.

Lifecore Biomedical, Inc.(NASDAQ:LFCR), a fully integrated injectables contract development and Manufacturing organisation, reported third-quarter 2026 financial results that showed a Revenue decline offset by notable new Business wins expected to contribute to future growth.

Third-Quarter Revenue and Margin Picture

Revenues for the quarter ended September 30, 2026, were $25.3 million, a decrease of $5.8 million, or 18.6%, compared to $31.1 million in Q3 2025. For the first nine months of the year, revenues totalled $82.7 million, down 21.8% from $105.7 million in the same period a year earlier.

Gross profit for the quarter was $6.8 million, compared to $7.8 million in Q3 2025. For the nine-month period, Gross Profit was $23.4 million, down from $34.7 million in the prior year.

Operating expenses declined 28.9% to $7.7 million in the quarter, compared to $10.9 million a year ago. The nine-month Operating Expense figure of $26.4 million represented a 27.5% decrease year-over-year, reflecting cost management efforts.

Net Loss and Cash Position

Net loss for Q3 2026 was $40.1 million, or $1.08 per diluted share, compared to a net loss of $10.0 million, or $0.29 per diluted share, in Q3 2025. The widened loss reflected non-cash and other items beyond the operating-level metrics. For the nine-month period, net loss was $61.2 million, or $1.70 per diluted share, compared to $20.9 million, or $0.64 per diluted share, in the prior year.

On the Cash Flow side, Lifecore generated $9.5 million from operations and $6.9 million in free cash flow for the nine months ended September 30, 2026. The company ended the quarter with approximately $38 million in total liquidity, comprising $23 million in cash and $15 million in revolving credit availability.

Adjusted EBITDA for Q3 was $4.0 million, up from $3.1 million in Q3 2025.

New Business Wins Drive Pipeline Growth

During the third quarter, Lifecore secured two new technology transfer projects. One supports process performance qualification batches for a biotech company's new drug application for a new chemical entity. The other supports a currently marketed product for a large pharmaceutical company. Management indicated that both programmes are expected to begin contributing to revenue in 2027.

Early in Q4 2026, the company signed three additional development-phase programmes, including a Phase 2 product with a top-20 global pharmaceutical company and two Phase 3 products with two separate biotech companies. These wins add to the company's high-value pipeline and reflect ongoing Demand for its integrated CDMO services.

Capacity and Operational Positioning

Lifecore operates as a fully integrated CDMO specialising in the development, fill, and finish of sterile injectable pharmaceutical products, including pre-filled syringes and vials. The company's capabilities span formulation development through commercial manufacturing, positioning it to capture programmes at various stages of clinical advancement.

Looking Forward

Lifecore's Q3 results present a mixed picture — declining revenue in the near term but a growing pipeline of new contracts that management expects will support long-term revenue growth beginning next year. The company's ability to convert its newly secured technology transfer and development-phase programmes into commercial-scale manufacturing revenue will be a key Factor in its trajectory.